AHB plans to issue H shares and list on the main board of the Hong Kong Stock Exchange
AHB plans to issue H shares and list on the main board of the Hong Kong Stock Exchange to advance its globalization strategy, enhance brand influence and core competitiveness, consolidate its industry-leading position, optimize capital structure, broaden financing channels, and improve corporate governance and overall strength
According to the announcement from Huaheng Biological (688639.SH), the company's board of directors has reviewed and approved the proposal regarding the issuance of H shares and the listing on the Hong Kong Stock Exchange Limited. In order to further advance the company's globalization development strategy, enhance brand influence and core competitiveness, consolidate its leading position in the industry, fully leverage the resource and mechanism advantages of the international capital market, optimize the capital structure, broaden diversified financing channels, and comprehensively improve the company's governance level and overall strength, the company plans to issue overseas listed foreign shares (H shares) and apply for listing on the main board of the Hong Kong Stock Exchange Limited (referred to as "Hong Kong Stock Exchange")
